Alliance Global Partners initiated coverage of MeaTech 3D (NASDAQ:MITC) with a “buy” rating and $11 price target. The stock closed at $3.55 on July 15. MeaTech is a cellular agriculture firm focused on developing human...
H.C. Wainwright launched coverage of Oyster Point Pharma (NASDAQ:OYST) with a “buy” rating and $20 price target. The stock closed at $4.43 on July 15. Oyster Point Pharma is a commercial stage biopharmaceutical company...
Research Capital downgraded Bellus Health (NASDAQ:BLU) to “hold” from “speculative buy” and removed its previous $14.50 price target so “we can properly account for the new dilution” from a $153-million offering of new...
Analysts for SVB Securities and Maxim Group downgraded ContraFect (NASDAQ:CFRX) after a data safety monitoring board recommended termination for futility of a Phase 3 trial evaluating exebacase in methicillin-resistant...
Dawson James downgraded Pluristem Therapeutics (NASDAQ:PSTI) to “neutral” from “buy” and removed its price target after a Phase 3 trial investigating muscle regeneration following hip surgery did not meet the primary...
Cantor Fitzgerald downgraded Humanigen (NASDAQ:HGEN) to “neutral” from “overweight” and slashed its price target to $2 from $30 after a failed COVID-19 study. The stock closed at $2.99 on July 12. The National Institute...
Stifel downgraded Atara Biotherapeutics (NASDAQ:ATRA) to “hold” from “buy” and lowered its price target to $5 from $16, following the company’s interim Phase 2 analysis with ATA188 for the treatment of multiple...
Alliance Global Partners downgraded OpGen (NASDAQ:OPGN) to “neutral” and lowered its price target to 67 cents, citing the company’s cash needs. The stock closed at 61 cents on July 11. “We view the company’s...
Alliance Global Partners downgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “buy” and reduced its price target to 14 cents from 65 cents, citing a fiscal second quarter preliminary revenue miss. The stock was...
Echelon Capital Markets initiated coverage of Mindset Pharma (CSE:MSET) with a “speculative buy” rating and price target of $1.25 (Canadian). The stock closed at 33 cents on July 6. Mindset develops patented psychedelic...